Biodesix (BDSX) Operating Expenses (2019 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Biodesix was $123.55 million, up 11.7% year-over-year; for FY2025, it came in at $116.37 million, up 10.0% from FY2024.

• Annual Operating Expenses has increased for three consecutive years, with a five-year compound annual growth rate of 11.2% (FY2020 to FY2025).
• In prior years, Biodesix's Operating Expenses was $105.82 million in FY2024 (+17.0%), $90.43 million in FY2023 (+1.8%), $88.8 million in FY2022 (-7.0%) and $95.45 million in FY2021 (+39.4%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses since Q1 2021.
• On a year-over-year basis, Operating Expenses has increased in each of the last ten quarters, with growth averaging 15.1% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2024, with growth of 29.4%; the weakest was Q1 2022, with a decline of 39.0%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $31.76 million (Q1 2026), $30.72 million (Q4 2025) and $28.82 million (Q3 2025).